Related references
Note: Only part of the references are listed.Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia
Konrad Aumann et al.
BLOOD (2013)
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
Jonas S. Jutzi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies
Ana Puda et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Jelena D. Milosevic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells
Lars A. Forsberg et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Joannah Score et al.
BLOOD (2012)
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Omar Abdel-Wahab et al.
CANCER CELL (2012)
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2
Kai B. Kaufmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Lambert Busque et al.
NATURE GENETICS (2012)
Detectable clonal mosaicism and its relationship to aging and cancer
Kevin B. Jacobs et al.
NATURE GENETICS (2012)
Detectable clonal mosaicism from birth to old age and its relationship to cancer
Cathy C. Laurie et al.
NATURE GENETICS (2012)
CUX1 transcription factor is required for optimal ATM/ATR-mediated responses to DNA damage
Charles Vadnais et al.
NUCLEIC ACIDS RESEARCH (2012)
The p53 network: cellular and systemic DNA damage responses in aging and cancer
H. Christian Reinhardt et al.
TRENDS IN GENETICS (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
Thorsten Klampfl et al.
BLOOD (2011)
JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation
Fan Liu et al.
CANCER CELL (2011)
Mouse models of myeloproliferative neoplasms: JAK of all grades
Juan Li et al.
DISEASE MODELS & MECHANISMS (2011)
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders
Jerry L. Spivak et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Deep sequencing reveals double mutations in cis of MPL exon 10 in myelloproliferative neoplasm's
Daniela Pietra et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes
Brady L. Stein et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Regulation of erythropoietin production
Wolfgang Jelkmann
JOURNAL OF PHYSIOLOGY-LONDON (2011)
DNMT3A mutations in myeloproliferative neoplasms
F. Stegelmann et al.
LEUKEMIA (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
p53 Lesions in Leukemic Transformation
Ashot Harutyunyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
Elena Crisa et al.
ANNALS OF HEMATOLOGY (2010)
Ubiquitination and degradation of the thrombopoietin receptor c-Mpl
Sebastian J. Saur et al.
BLOOD (2010)
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
Philip A. Beer et al.
BLOOD (2010)
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2
Wei Wang et al.
BLOOD (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
Martin Sauvageau et al.
CELL STEM CELL (2010)
Stem cells and the aging hematopoietic system
Isabel Beerman et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations
Frank Stegelmann et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
A. Pardanani et al.
LEUKEMIA (2010)
Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells
J-J Kiladjian et al.
LEUKEMIA (2010)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
R. Jaeger et al.
LEUKEMIA (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
LNK Mutations in JAK2 Mutation-Negative Erythrocytosis.
Terra L. Lasho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion
Isabel Beerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses
Yvonne Suessmuth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Mark A. Dawson et al.
NATURE (2009)
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Mamta Tahiliani et al.
SCIENCE (2009)
Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives
Isabelle Plo et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies
Andrew J. Dunbar et al.
CANCER RESEARCH (2008)
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution
Franca Radaelli et al.
HEMATOLOGY (2008)
Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases
Luciana Teofili et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription
Kyunghwan Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes
Mary Truscott et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xl levels
Gen Kano et al.
LEUKEMIA & LYMPHOMA (2008)
Hematopoietic cytokine receptor signaling
S. J. Baker et al.
ONCOGENE (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
Polycythemia vera is not initiated by JAK2(V17F) mutation
Roberto H. Nussenzveig et al.
EXPERIMENTAL HEMATOLOGY (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Transgenic mice expressing the p75 CCAAT-displacement protein/cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia
Chantal Cadieux et al.
CANCER RESEARCH (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor
Yang-Sook Cho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
XH Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The Cbl interactome and its functions
MHH Schmidt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
W Tong et al.
BLOOD (2005)
ETV6: A versatile player in leukemogenesis
SK Bohlander
SEMINARS IN CANCER BIOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia
H Harada et al.
BLOOD (2004)
Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis
W Tong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Thrombopoietin signalling in physiology and disease
B Fishley et al.
GROWTH FACTORS (2004)
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
P Saharinen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a
T Yokochi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Haematopoietic cell-fate decisions, chromatin regulation and ikaros
K Georgopoulos
NATURE REVIEWS IMMUNOLOGY (2002)
Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping
MD Odero et al.
GENES CHROMOSOMES & CANCER (2001)
Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation
K Lindauer et al.
PROTEIN ENGINEERING (2001)
Development of pegylated interferons for the treatment of chronic hepatitis C
A Kozlowski et al.
BIODRUGS (2001)
Share Paper
